Skip to content

Aridis Pharmaceuticals, Inc.

CIK 0001614067

← back to feed
Revenue (TTM)
$21.55M
+64.6% YoY Q3 Sep 2023
Net Income (TTM)
−$2.99M
−486.8% YoY Q3 Sep 2023
EPS Diluted (TTM)
−$0.59
−54.5% YoY Q3 Sep 2023
Gross Margin
—
Q3 Sep 2023
Operating Margin
-4.1%
Q3 Sep 2023
Net Margin
-13.9%
Q3 Sep 2023
Free Cash Flow (TTM)
−$23.24M
Q3 Sep 2023
Cash
$35K
Q3 Sep 2023
Total Debt
—
Q3 Sep 2023
Shares Outstanding
44.57M sh
Q3 Sep 2023

Revenue & Net Income

EPS (Diluted)

Margins

Cash Flow

Revenue Growth (YoY)

Balance Sheet

Cash vs Debt

Recent filings